Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

EXL01 in Combination With Nivolumab for Advanced NSCLC Refractory to Immunotherapy

NCT06448572 is registered in ClinicalTrials.gov with University Hospital, Lille as lead sponsor.

NCT NCT06448572
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06448572 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
EXL01 in Combination With Nivolumab for Advanced NSCLC Refractory to Immunotherapy
Lead sponsor
University Hospital, Lille
Phase
Phase 1/2
Overall status
Recruiting
Start date
July 16, 2024
Completion date
October 1, 2028
Enrollment
21 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer